Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 21, 2016

Tenax completes enrolment for Phase III cardiac surgery trial of levosimendan

US-based specialty pharmaceutical company Tenax has completed patient enrolment in its Phase III LEVO-CTS trial of Levosimendan to be used during cardiac surgery.

US-based specialty pharmaceutical company Tenax has completed patient enrolment in its Phase III LEVO-CTS trial of Levosimendan to be used during cardiac surgery.

Discovered and developed by Orion Pharma, levosimendan is an intravenously administered calcium sensitiser for patients with acute decompensated congestive heart failure (CHF).

At therapeutic dosages, levosimendan improves myocardial contractility without increasing oxygen requirements and causes coronary and systemic vasodilation.

The double-blind, randomised, placebo-controlled LEVO-CTS study will test the use of levosimendan administered before and during cardiac surgery to reduce the incidence of low cardiac output syndrome (LCOS) and associated morbidity and mortality.

"We are very pleased to reach this milestone after more than two years of hard work, and would like to thank all of the patients and investigators who have taken part in the trial."

The secondary endpoints of the trial will determine the potential pharmacoeconomic benefits and the incidence rate of LCOS resulted by the administration of levosimendan.

The study has enrolled a total of 880 patients.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Tenax Therapeutics CEO John Kelley said: “We are very pleased to reach this milestone after more than two years of hard work, and would like to thank all of the patients and investigators who have taken part in the trial.

“Consistent clinical execution and increased trial visibility has significantly accelerated the enrolment rate during these past 12 months, and we believe the expanded number of patients ensures that we have the best possible chance for success.

“We now look forward to sharing top-line results with you during the next few months, and we are prepared for a near-term NDA submission and commercial effort if the data reads out positively. We continue to believe that levosimendan has the potential to fill an important void in the current treatment paradigm for cardiac surgery.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU